In a report released today, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $45.00. The company’s shares closed yesterday at ...
Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...
Spatial videos can be exported directly to a user's Photos library, viewed immediately on Vision ... Offering new tools like Magnetic Mask and the highly anticipated... at 18:02 PTC Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback